Pharmaceuticals
CHEPLAPHARM to Accelerate Global Supply Chain Digitalization with TraceLink MINT
The German pharmaceutical company unifies its digital partner network, laying the foundation for AI-driven supply chain orchestration BOSTON, May 14, 2026 /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network, today announced that the German-based but globally active CHEPLAPHAR...
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SEOUL, South Korea and...
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) appro...
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Bi...
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia ...
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug...
New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats
Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics. CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/ -- New global analysis of antiviral compounds released today has identified a critically thin pipeline of treatments in development tha...
Avalere Health expands to Japan with a full-service Advisory, Medical, and Marketing offering, led by industry veteran Junji Yokokawa
Avalere Health Japan is designed with the full healthcare experience in mind, launching with an elite integrated team that brings together market access, medical, and marketing specialists, along with strategic consulting expertise. TOKYO, May 11, 2026 /PRNewswire/ -- Avalere Health, a global str...
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
TOKYO, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficient drug discov...
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
SEOUL, South Korea, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficien...
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review ...
ABEC Expands Process Sciences Group to Strengthen Bioprocess Optimization Capabilities
BETHLEHEM, Pa., May 6, 2026 /PRNewswire/ -- ABEC, a global leader in bioprocess engineering solutions, announced the expansion of itsProcess Sciences group, expanding its ability to help biopharmaceutical manufacturers accelerate development, reduce risk, and improve productivity across the biopr...
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
SUZHOU, China and MÖLNDAL, Sweden, May 6, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with Boehringer ...
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry ...
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
HONG KONG, May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on...
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...
BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development
decisions,
reducing risk and accelerating patient impact
SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost & Sullivan
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
MELBOURNE, Australia and INDIANAPOLIS, Ind., May 5, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology[1], demonstrating that TLX250‑Px (Zircaix®[2], 89 Z...
CARiNG Pharmacy Introduces "Empowering Women, Inspiring Wellness" Campaign to Encourage Women to be More Proactive About Their Health
The new campaign focuses on a holistic approach to women's health by connecting inner wellness, outer wellbeing and mental health in everyday life KUALA LUMPUR, Malaysia, May 4, 2026 /PRNewswire/ -- CARiNG Pharmacy, together with Georgetown Pharmacy and Wellings Pharmacy under BIG CARING Group, h...
XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway
SHENZHEN, China, May 4, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has succes...
Week's Top Stories
Most Reposted
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 297 media titles]
2026-05-12 10:15Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 293 media titles]
2026-05-11 16:20Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 290 media titles]
2026-05-12 10:00Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 283 media titles]
2026-05-12 14:00Amity's Singapore-Headquartered AI Research Center Wins Gold at Taiwan's 2026 Best AI Awards
[Picked up by 280 media titles]
2026-05-13 08:00